OSE Immunotherapeutics delays H1 2026 results amid financing talks

Bitget2026/09/28 05:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OSE Immunotherapeutics deferred publication of its H1 2026 financial statements and interim financial report to a later date.
The delay was tied to ongoing financing efforts aimed at extending cash runway beyond 2026.
Cash totaled € 11.1 million at June 30, down from € 17.0 million at March 31; runway confirmed through December 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280130PRIMZONEFULLFEED1001274817) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OSE Immunotherapeutics delays H1 2026 results amid financing talks

You may also like

Crypto prices